Clinical trials: Lymphomas,
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant
RATIONALE: Zoledronic acid, vitamin D, and calcium may prevent bone loss in patients who are undergoing donor stem cell transplant.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Osteoporosis
- Trial name
- NCT00321932
- Testing
- calcium, cholecalciferol, zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Minnesota
Lymphoma
Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma
This phase II clinical trial studies how well yttrium Y 90 ibritumomab tiuxetan, rituximab, and high-dose chemotherapy followed by peripheral blood stem cell transplant in treating patients with relapsed B-cell non-Hodgkin…
- Trial name
- NCT00695409
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- City of Hope Medical Center
Diffuse Large B-cell Lymphoma Refractory, Follicular B-cell Non-Hodgkin's Lymphoma
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
This is a randomized, open-label, multicenter, Phase 2 clinical trial designed to evaluate the efficacy and safety of brentuximab vedotin in combination with rituximab and bendamustine for the treatment of patients with relapsed…
- Trial name
- NCT02594163
- Testing
- Brentuximab Vedotin, Rituximab, Bendamustine
- Where
- 50 sites in United States, Czechia and 5 more
- Volunteers
- 25 people
- Sponsor
- Seagen Inc.
Cardiac Toxicity, Chemotherapeutic Agent Toxicity
Cardiac Magnetic Resonance Imaging in Patients With Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin
RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.
- Conditions
- Cardiac Toxicity, Chemotherapeutic Agent Toxicity, Lymphoma
- Trial name
- NCT00577798
- Testing
- contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
This phase II trial studies how well combination chemotherapy with or without rituximab works in treating participants with stage III-IV classic Hodgkin lymphoma.
- Conditions
- Classic Hodgkin Lymphoma, Lugano Classification Stage III Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Hodgkin Lymphoma AJCC v8
- Trial name
- NCT00654732
- Testing
- Bleomycin, Dacarbazine, Doxorubicin Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
- Trial name
- NCT04930536
- Testing
- Acalabrutinib capsule
- Where
- 15 sites in India
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Acute Leukemia, Acute Myeloid Leukemia
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Burkitt's Lymphoma
- Trial name
- NCT02722668
- Testing
- Fludarabine, Cyclophosphamide, MMF
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- COSMOS (NCT02639910)
- Testing
- Tafasitamab, Idelalisib, Venetoclax
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 24 people
- Sponsor
- MorphoSys AG
Knee Osteoarthritis
Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial
The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis.
- Trial name
- NCT02083861
- Testing
- Sam Ultrasonic Diathermy Device
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- ZetrOZ, Inc.
Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
The purpose of this Phase 1/2 study is to evaluate the safety and efficacy of Loncastuximab Tesirine (ADCT-402) in combination with Ibrutinib in participants with Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma.
- Trial name
- NCT03684694
- Testing
- Loncastuximab Tesirine, Ibrutinib
- Where
- 35 sites in United States, Belgium and 4 more
- Volunteers
- 136 people
- Sponsor
- ADC Therapeutics S.A.
Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse
CT-011 MAb in DLBCL Patients Following ASCT
Autologous peripheral blood stem cell transplantation combined with high dose chemotherapy is the treatment of choice given to patients with diffuse large-B cell lymphoma (DLBCL) following relapse of the disease.
- Conditions
- Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
- Trial name
- NCT00532259
- Testing
- CT-011
- Where
- 27 sites in United States, India and 1 more
- Volunteers
- 72 people
- Sponsor
- CureTech Ltd
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Malignant Solid Tumor, Lymphomas
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies.
- Trial name
- DINAMIC (NCT01359982)
- Testing
- RRx-001
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- EpicentRx, Inc.
Marginal Zone B-cell Lymphoma
Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma (SMZL) is a well-defined low-grade B-cell lymphoma,considered as a rare neoplasm accounting for about 2% of all non-Hodgkin's lymphomas (NHL) and represents for most cases of otherwise…
- Trial name
- NCT02853370
- Testing
- Bendamustine and Rituximab
- Where
- 30 sites in France, Italy
- Volunteers
- 78 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Lymphoma, Myeloma
Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
Allogeneic transplantation is used to treat many malignant and non-malignant diseases, though the potential toxicities of the procedure remain high.
- Conditions
- Lymphoma, Myeloma, Leukemia, Myelodysplasia
- Trial name
- NCT00578942
- Testing
- Campath Purged Non-myeloablative ASCT
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- David Rizzieri, MD
Mantle Cell Lymphoma
A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial
To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.
- Trial name
- EMERGE (NCT00737529)
- Testing
- lenalidomide
- Where
- 70 sites in United States, Austria and 12 more
- Volunteers
- 134 people
- Sponsor
- Celgene
Related Donors Donating PBSC to a Family Member, Healthy Donors
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies.
- Conditions
- Related Donors Donating PBSC to a Family Member, Healthy Donors, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT04762875
- Testing
- MGTA-145, Plerixafor
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Ensoma
T-cell Non-Hodgkin Lymphoma
CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
The current standard of care for the frontline treatment of peripheral T-cell lymphomas (PTCL) is induction chemotherapy followed by autologous stem cell transplantation (ASCT).
- Trial name
- NCT01746173
- Testing
- Cyclophosphamide, Doxorubicin, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Dana-Farber Cancer Institute
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.